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INTRODUCTION
Oral anticoagulation with warfarin is the established method
for treatment and prophylaxis of thromboembolic diseases
(1, 2). While the efficacy of warfarin on anticoagulation is
well established, it can cause a potentially fatal complication,
hemorrhage. Hemorrhage develops in as many as 9.6% of
patients annually, including a fatal case rate of 0.6% (3). 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the
most widely used drugs to control musculoskeletal pain or in-
flammation. In addition to their antiplatelet function, NS-
AIDs can affect the pharmacologic action of warfarin through
their direct interaction. High protein binding and the cyto-
chrome P450 (CYP)-dependent clearance mechanisms of
NSAIDs can affect the serum levels of warfarin (4-6). Accord-
ingly, there have been many case reports describing bleeding
complications after NSAIDs were administered along with
warfarin (7-13). 
The level of anticoagulation with warfarin is usually mon-
itored with international normalized ratio (INR), which is a
strong predictor of future bleeding risk (2); every one-point
increase in INR increases bleeding risk by 54.0% (14). There-
fore, monitoring INR is essential when prescribing warfarin.
In this respect, discontinuing of NSAIDs or adjusting war-
farin dose should be considered if INR increases after addi-
tion of a NSAID. 
In this study, we investigated the risk factors for INR in-
crease in respect to warfarin and NSAIDs. The results of our




A total of 2,652 warfarin users were confirmed who began
to take NSAIDs at the outpatient clinics of Seoul National
University Hospital between January 2000 and August 2006.
The patients fulfilling the following criteria were recruited
for the study: 1) Maintenance warfarin dose was stabilized
for at least 3 months before adding a NSAID. Stabilization
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Risk Factors of Drug Interaction between Warfarin and Nonsteroidal
Anti-Inflammatory Drugs in Practical Setting
Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to interact with the oral
anticoagulant warfarin and can cause a serious bleeding complication. In this study,
we evaluated the risk factors for international normalized ratio (INR) increase, which
is a surrogate marker of bleeding, after addition of an NSAID in a total of 98 patients
who used warfarin. Patient age, sex, body mass index, maintenance warfarin dose,
baseline INR, coadministered medications, underlying diseases, and liver and kid-
ney functions were evaluated for possible risk factors with INR increase ≥15.0%
as the primary end-point. Of the 98 patients, 39 (39.8%) showed an INR elevation
of ≥15.0% after adding a NSAID to warfarin therapy. Multivariate analysis showed
that high maintenance dose (>40 mg/week) of warfarin (P=0.001), the presence of
coadministered medications (P=0.024), the use of meloxicam (P=0.025) and low
baseline INR value (P=0.03) were the risk factors for INR increase in respect to
NSAID-warfarin interaction. In conclusion, special caution is required when an NSAID
is administered to warfarin users if patients are taking warfarin >40 mg/week and
other medications interacting with warfarin. 
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Target INR value was 2.0-3.0, 2) INR values after addition
of NSAIDs were available, 3) The warfarin dose did not change
after adding a NSAID, and the administered NSAID dose
remained constant, 4) The age of the patient was 18 yr and
older. Ninety eight patients fulfilled all of the above criteria.
The Institutional Review Board of Seoul National Univer-
sity Hospital approved this study. All of the data were man-
aged after the deidentification process. 
Study design
This study was a retrospective case control study using
medical records in a tertiary hospital. For each patient, the
following data were collected from the medical records or
anticoagulation service team records: age, sex, body mass
index (BMI), underlying diseases, species of NSAIDs, indi-
cation and dosage of warfarin, INR values before and after
the administration of the NSAIDs, baseline liver function
tests (alanine aminotransferase, aspartate aminotransferase),
and drugs coadministered with warfarin and NSAIDs. Liver
function test abnormalities were defined as elevation of aspar-
tate aminotransferase (AST) or alanine aminotransferase (ALT)
above the upper range of reference values (40 IU/mL). Pro-
thrombin time (INR) was determined using the STAR ana-
lyzer, an automated nephelometric coagulation laboratory
analyzer (Diagnostica Stago, Asieres, France). The intra- and
inter-assay coefficients of variations (CV) of prothrombin time
(PT) were 1.3% and 2.3%, respectively. Baseline INR value
was defined as the last INR value before a NSAID was added.
Mean duration between the point when the INR was mea-
sured and a NSAID was added was 17.4±11.7 days. The
first INR value measured after adding a NSAID was used
for comparison with the baseline value. 
Between the cases and controls of the study, the case was
defined as those in whom INR was increased more than 15%
after addition of a NSAID and the controls were defined as
the rest of the patients. INR increase of ≥15% was chosen
because an INR increase of <15.0% can occur as a result of
test variability (7). Finally, risk factors for INR increase were
explored for subjects and controls. 
Statistical analysis
To explore the risk factors associated with INR increase,
age, sex, BMI, underlying diseases, species of NSAIDs, indi-
cations for warfarin, maintenance dose of warfarin, baseline
PT (INR), baseline liver function test results, baseline renal
function test results, and the presence of coadministered medi-
cations were regarded as independent variables. The presence
of INR increase was regarded as a dependent variable. 
Logistic regression analysis was applied to compare the
cases and controls. After performing univariate analysis with
each independent variable described above, multivariate anal-
ysis was done to infer the best model to explain INR increase
after adding a NSAID. Independent variables which showed
P<0.100 in univariate analysis (age, baseline INR value, main-
tenance warfarin dose and meloxicam) and a variable which
appeared consistently in the models predicted by the progres-
sive or deletion model (coadministered medication) were cho-
sen as independent variables to infer the best model. All sta-
tistical analyses were done with SPSS 12.0 for Windows (SPSS,
Inc., Chicago, IL, USA).
RESULTS
Characteristics of the study population
The study population consisted of 98 patients; the char-
acteristics of whom are summarized in Table 1. Heart valve
replacement was the most common indication for warfarin,
followed by cerebral infarction, atrial fibrillation and venous
thromboembolism. There were no patients who used more
than one NSAID at a time. Of the 98 patients, 39 (39.8%)
showed an INR elevation of ≥15.0% after adding a NSAID
to warfarin therapy. 
Eighty patients used other medications than warfarin or
NSAIDs; among these, 42 patients were taking comedica-
tions which might interact with warfarin (15). The comedi-
cations included acetaminophen, amiodarone, aspirin, benzb-
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*mg/week; 
� Comedications with known interaction with warfarin.
NSAIDs, nonsteroidal anti-inflammatory drugs.
Characteristics






Sex (female:male) 26:13 33:26
Age (mean±SD) (yr) 57.6±13.0 61.6±9.6
Body mass index (mean±SD) 22.3±3.5 23.0±3.6
Indications for warfarin (%)
Heart valve replacement 24 (61.5) 39 (66.1)
Cerebral infarction 6 (15.4) 5 (8.5)
Atrial fibrillation 4 (10.3) 10 (16.9)
Venous thromboembolism 5 (12.8) 5 (8.5)
Maintenance dose* of warfarin  33.6±10.8 28.3±10.0
(mean±SD)
NSAIDs used (%)
Aceclofenac 14 (35.9) 18 (30.5)
Celecoxib 4 (10.3) 11 (18.6)
Meloxicam 8 (20.5) 5 (8.5)
Naproxen 5 (12.8) 7 (11.9)
Rofecoxib 1 (2.6) 7 (11.9)
Fenoprofen 3 (7.7) 4 (6.8)
Zaltoprofen 3 (7.7) 4 (6.8)
Ibuprofen 1 (2.6) 3 (5.1)
Comedications
�(%) 20 (51.3) 22 (37.3) 
Table 1. Characteristics of the study population romarone, bezafibrate, cefdinir, ceftizoxime, cilostazol, clopi-
dogrel, deflazacort, fluconazole, hydrocortisone, indapamide,
magnesium oxide, metronidazole, omeprazole, prednisolone,
rosuvastatin, sertaconazole, simvastatin, SK1306X, sulfasa-
lazine, sultamicillin, tramadol, trazodone, trimebutine, and
valproic acid.
Among the 39 patients who experienced more than 15%
of INR increase, 6 patients (15.4%) had to decrease the dose
of warfarin after stopping it at least for 1 day and 19 patients
(48.7%) had to decrease the dose of warfarin. Among the 59
patients who did not experience more than 15% INR increase,
only three patients (5.1%) had to decrease the dose of war-
farin. Five bleeding episodes were noted, including one in-
tracranial hemorrhage (ibuprofen), two epistaxis (fenoprofen
and aceclofenac), one hemoptysis (ibuprofen) and one mus-
cle hematoma (fenoprofen).
Risk factors for INR increase
As summarized in Table 2, age, baseline INR value, main-
tenance warfarin dose and the administration of meloxicam
were associated with INR increase after administration of a
NSAID in univariate analysis with P<0.100. In multivariate
analysis, high maintenance dose of warfarin (P<0.001), the
presence of coadministered medications (P=0.02), the use of
meloxicam (P=0.03), and low baseline INR value (P=0.03)
were finally fitted into the final model (Table 3). 
DISCUSSION
In this study, we showed that initiating NSAIDs in war-
farin users could increase INR in 39.8% of the patients. Pati-
ents who had maintenance doses of warfarin >40 mg/week
took warfarin-interacting medications and used meloxicam
were more susceptible to INR increase when a NSAID was
added. 
We chose INR increase as the clinical endpoint of the study.
Measurement of INR is the standard monitoring method in
warfarin users for predicting bleeding complications (1, 2).
Therefore, meticulous monitoring of INR is accepted as a
reasonable approach to prevent bleeding complication when
NSAIDs are administered to patients taking warfarin (10,
16). Since the fatal hemorrhagic complications can occur with-
out any preceding minor bleeding, adjustment of medica-
tion should be strongly considered if INR increases. 
We defined an INR increase of more than 15.0% as signif-
icant in this study. Test variability of INR measurement is
known to be 15.0% and this cut-off value was used in anoth-
er study (7). Furthermore, test variability of PT in our hos-
pital is less than 2.5%. Whether 15.0% increase is clinical-
ly significant may be controversial. However, to the best of
our knowledge, there has been no clear guideline on which
percent increase of INR is clinically safe or risky.
It has not been previously reported that the patients who
need high maintenance doses of warfarin are more vulnera-
ble to drug-interaction with NSAIDs. More saturation of
plasma proteins or metabolic enzymes with warfarin might
be the cause of more frequent drug interactions. Presence of
coadministered medications other than warfarin or NSAIDs
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Variables Odds ratio (95% CI) P value
Age 0.97 (0.93-1.01) 0.09
Sex
Male 0.64 (0.27-1.47) 0.29
Female 1.00 -
Body mass index 0.94 (0.83-1.07) 0.35
LFT abnormalities 0.66 (0.13-3.48) 0.62
Indication for warfarin
Atrial fibrillation 3.00 (0.57-15.77) 0.19
Venous thromboembolism 2.50 (0.46-13.65) 0.29
Heart valve replacement 1.55 (0.43-5.46) 0.51
Cerebral infarction 1.00 -
Baseline INR     0.310 (0.09-1.08) 0.07
Warfarin dose (mg/week) 
>40 13.00 (2.34-72.14) 0.003
20-40 4.76 (1.00-22.68) 0.05
<20 1.00 -
NSAIDs
Meloxicam 11.20 (1.04-120.36) 0.046
Zaltoprofen 5.25 (0.40-68.95) 0.21
Fenoprofen 5.25 (0.40-68.95) 0.21
Naproxen 5.00 (0.46-54.51) 0.19
Aceclofenac 5.44 (0.60-49.56) 0.13
Celecoxib 2.55 (0.23-27.71) 0.44
Ibuprofen 2.33 (0.11-50.98) 0.59
Rofecoxib 1.00 -
Co-medications 1.77 (0.78-4.02) 0.17
Table 2. Risk factors for INR increase with respect to the inter-
action of NSAIDs and warfarin (univariate analysis)
NSAIDs, nonsteroidal anti-inflammatory drugs; LFT, liver function test
(Liver function test abnormalities were defined as elevation of AST or
ALT above the upper range of reference level.); INR, International Nor-
malized Ratio; CI, confidence interval.
Variables Odds ratio (95% CI) P value
Age 0.98 (0.93-1.02) 0.24
Baseline INR 0.20 (0.05-0.86) 0.03
Warfarin dose (mg/week)
>40 19.46 (3.15-120.34) 0.001
20-40 4.87 (1.04-22.71) 0.04
<20 1.00
Comedications 3.16 (1.17-8.54) 0.02
Meloxicam 4.88 (1.23-19.45) 0.03
Table 3. Risk factors for INR increase in interaction of NSAIDs
and warfarin (multivariate analysis)
INR, International Normalized Ratio; NSAIDs, nonsteroidal anti-inflam-
matory drugs; CI, confidence interval. was another risk factor for INR increase. As described in the
methods section, the study population used a wide range of
comedications which were known to interact with warfarin.
Therefore, the presence of coadministered medication as a risk
factor is reasonably expected result. Heterogeneity of comed-
ications among the study population may result in pleiotrop-
ic effects. However, the result of our study reflects practical
clinical settings where patients have different kinds of comor-
bid conditions requiring different kinds of medications. Low
baseline value of INR was also a risk factor for INR increase
(P=0.03). This result comes from the fact that we defined
INR increase as percent increase rather than absolute increase. 
Among the NSAIDs tested in this study, meloxicam was
found to be a risk factor for INR increase in warfarin users.
Turck et al., however, reported that meloxicam lacked inter-
action with warfain (17). Such divergent results can be ex-
plained as follows. First, clinical settings were different; the
previous report was on 13 healthy persons, while our study
represents real clinical settings where distinct kinds of med-
ications were concomitantly used. Second, response to war-
farin varies depending on ethnicity (18-20). This difference
is now beginning to be explained by genetic polymorphisms
of the metabolic enzymes. Since induction or suppression of
enzymes is one of the mechanisms of drug interaction bet-
ween NSAIDs and warfarin, genetic difference of these meta-
bolic enzymes may affect the INR level after the addition of
NSAIDs (21, 22).
However, a cautious approach is needed for interpretation
of the NSAID results for the following reasons. First, we test-
ed only eight kinds of NSAIDs. The results should be inter-
preted in the context of the other seven NSAIDs. Second, there
was no bleeding case with meloxicam in this study. Bleeding
might be prevented with early detection of INR increase. If
we consider bleeding cases of ibuprofen, fenoprofen and ace-
clofenac in our study, celecoxib or naproxen may be recom-
mended as first line NSAIDs in warfarin users. A prospective
study with a large number of patients is warranted to prove
this suggestion. A careful approach is still needed when adding
a NSAID in warfarin users, regardless of its class, until our
suggestion is proven. 
Liver function test abnormalities were not a risk factor in
our patient group. These results are consistent with a previ-
ous report that the disposition of warfarin is not affected by
mild or moderate hepatic impairment (23). However, since
maximal levels of AST and ALT were within 5 times of the
upper range, a cautious approach is needed when applying
our results to the patients who have severe liver function abnor-
malities.
Interindividual variability in the response to warfarin is
now beginning to be explained by pharmacogenetic poly-
morphisms. Polymorphisms of cytochrome P450 2C9 and
VKORC1 genes are most commonly studied for this app-
roach (22, 24). For NSAID-warfarin interaction, Malhi et al.
reported that a patient who experienced extensive bleeding
after introduction of celecoxib was a heterozygote with CY-
P2C9*2 and *3 alleles, which were associated with low meta-
bolism (25). These results suggest that pharmacogenetic test-
ing may be useful to refine the risk group for NSAID-war-
farin interaction. Further studies are warranted on the role
of genetic polymorphisms on the risk of NSAID-warfarin
interaction.
There are several limitations in this study. First, the num-
ber of patients was limited so that all of the potential con-
founding variables which could affect the INR level could
be evaluated simultaneously. We could enroll only 98 pati-
ents out of 2,652 candidates because INR was not measured
in most of the cases after the addition of a NSAID. The low
number of patients might produce a type I and II errors in the
interpretation. Second, the endpoint of the study was the INR
value, a surrogate marker of hemorrhage rather than bleed-
ing although bleeding may be more clinically important end-
point. However, considering the potential seriousness of bleed-
ing, clinicians may still have to use INR as a guideline for
deciding their strategy when using warfarin. In this sense,
our result will be helpful for clinicians.
In conclusion, high maintenance dose of warfarin, the pres-
ence of coadministered medications, the use of meloxicam
and low baseline INR value are the risk factors for INR in-
crease in respect to NSAID-warfarin interaction. 
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